Development of Protein-Based Biological Drugs for Parkinson’s Disease. The aim of the project is to develop a protein-based therapy that is highly specific against the most toxic forms of aggregates in Parkinson’s disease. The project involves the creation, design, and production of antibodies and other binders, as well as analyzing these in vitro to understand how they affect aggregation. Methods used include protein purification with the ÄKTA system, ThT aggregation assays, mass photometry, and toxicity studies in cell assays. We are looking for a motivated person who is good at communication, collaboration and to work independently and who contributes to the nice atmosphere in the group. When selecting the candidate communication and collaboration skills will be important.
We are currently looking for a person with documented experience in the development of biological drugs and who holds a PhD in Parkinson’s disease and biological drugs. The person should be able to work with and have documented experience in the ÄKTA system (affinity purifications, ion exchange columns, and SEC), cell lines and toxicity studies, aggregation assays, Ligand Tracer and other affinity measurements, ELISA, PyMol, and protein design. Some administrative and teaching-related tasks may also be included in the position.
It is advantageous if you have experience with in vitro experiments such as flow cytometry.